Announcement of the results of extraordinary safety committee meetings
“There is no overall link to the risk of thrombosis.
There is a very rare possibility of blood clots
AstraZeneca vaccine. Reuters Yonhap News
The European Medicines Agency (EMA) announced that the benefits of the COVID-19 vaccination jointly developed by the multinational pharmaceutical company AstraZeneca and the University of Oxford in the UK are greater than the risk. The European Medicines Agency held an extraordinary meeting of the Safety Committee on the 18th and announced that it had no overall link between the Astrazeca vaccine and the increased risk of blood clotting’thrombosis’. The European Medicines Agency said that the benefits of getting AstraZeneca vaccine still outweigh the risk of side effects, and there is no evidence that there is a problem with the specific manufacturing site of the AstraZeneca vaccine. However, the European Medicines Agency said, “It may be related to a very rare blood clot related to platelet reduction.” The European Medicines Agency is the agency responsible for the evaluation and approval of drugs and vaccines in the European Union (EU). European Medicines Agency Commissioner Emma Cook said that “the link cannot be completely ruled out” between the rare blood clot and the AstraZeneca vaccine, the (AP) news agency said. “Our scientific position is that this vaccine is a safe and effective option to protect citizens from COVID-19. This (AstraZeneca vaccine) has been shown to be at least 60% immune in clinical trials. And, in fact, in practice (inoculation) showed that the immune effect was higher than in clinical trials.” Earlier, on the 7th, Austrian health authorities stopped vaccinating the company’s vaccine, claiming that two medical staff were killed due to blood clotting disorders after vaccination with the AstraZeneca vaccine. Subsequently, Denmark, Iceland, Bulgaria, Norway, and France have stopped vaccinating part or all of the AstraZeneca vaccine. The news agency said the announcement by the European Medicines Agency opened the way for European countries that have stopped vaccinating AstraZeneca to resume immunization. The UK’s Medicines and Health Care Products Regulatory Agency (MHRA) also announced that there was no evidence that the AstraZeneca vaccine caused blood clots. However, the UK Drug and Health Care Product Regulatory Authority also added that “five cases of cerebral thrombosis, a very rare and specific type of cerebral blood clots with platelet reduction, have been reported and are under further investigation.” By Jo Ki-won, staff reporter